Cancer Gene Therapy Market to Surge to US$ 19.97 Billion by 2033, Driven by Advancements in Gene-Induced Immunotherapy and Precision Oncology | DataM Intelligence

According to DataM Intelligence, the global cancer gene therapy market reached US$ 3.97 billion in 2024 and is expected to reach US$ 19.97 billion by 2033, growing at a CAGR of 19.8% during the forecast period 2025-2033. Growth is driven by rising prevalence of cancer, increasing adoption of personalized medicine, technological advancements in gene therapy techniques, and expansion of targeted therapy applications.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/cancer-gene-therapy-market?jd

North America (Largest Regional Share) - Key Industry Developments
North America dominated the market with a 43.5% revenue share in 2024, supported by advanced healthcare infrastructure, strong R&D investments, and regulatory support for innovative therapies.
✅ November 2025: Novartis AG expanded its CAR-T and gene therapy clinical programs targeting solid tumors across U.S. and Canada.
✅ October 2025: Pfizer entered a strategic partnership with leading cancer centers to accelerate development of gene-induced immunotherapies for lung and breast cancers.
✅ September 2025: Bluebird Bio, Inc. launched new clinical trials for oncolytic virotherapy in North American hospitals, enhancing access to innovative cancer treatments.

Asia-Pacific (Fastest-Growing Region) - Key Industry Developments
Asia-Pacific is the fastest-growing region, projected to grow at a CAGR of 8.1% over the forecast period, driven by increasing healthcare expenditure, rising cancer prevalence, and supportive government policies in China, India, Japan, and Southeast Asia.
✅ November 2025: Adaptimmune Therapeutics expanded its gene therapy collaborations with hospitals and research institutes in Japan and Singapore to accelerate clinical studies.
✅ October 2025: Krystal Biotech, Inc. established a manufacturing hub in China for advanced gene therapy vectors, targeting solid tumor treatment demand.
✅ September 2025: Regulus Therapeutics initiated Asia-Pacific-focused studies on gene transfer therapies, in partnership with academic oncology research centers.

Key Mergers and Acquisitions (2025)
✅ Strategic Gene Therapy Acquisition: Novartis AG acquired a U.S.-based gene therapy startup to strengthen its portfolio in solid tumor immunotherapies.
✅ Technology Expansion: Pfizer completed the acquisition of a biotechnology firm specializing in ex vivo gene editing to enhance its cancer gene therapy pipeline.

Purchase this report before year end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=cancer-gene-therapy-market
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis
By Technique: In vivo gene therapy leads the market, complemented by ex vivo approaches for precision oncology.
By Therapy: Gene-induced immunotherapy holds the largest share (44.1% in 2024), followed by oncolytic virotherapy and gene transfer therapies.
By Application: Lung, breast, and liver cancers dominate the therapy applications, reflecting high incidence and unmet medical needs.
By End-User: Hospitals and cancer centers represent the majority of therapy administration, supported by specialized treatment protocols.

Regional Insights
North America leads due to advanced clinical research, established oncology centers, and strong regulatory support. Asia-Pacific is the fastest-growing region, driven by increasing healthcare investments, clinical trial expansion, and rising cancer incidence. Europe demonstrates steady growth with supportive regulatory frameworks and adoption of gene therapies.

Growth Drivers
1. Rising prevalence of cancers worldwide
2. Advances in gene editing and immunotherapy technologies
3. Increasing adoption of personalized and targeted oncology therapies
4. Expansion of clinical trial networks and hospital partnerships
5. Supportive government policies and incentives for biotech innovation

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-gene-therapy-market?jd

Key Players
The cancer gene therapy market includes leading companies such as Novartis AG, Pfizer, Adaptimmune Therapeutics, Bluebird Bio, Inc., Krystal Biotech, Inc., Regulus Therapeutics, and BioGenera, among others.

Key Highlights (Top 5 Key Players)
1. Novartis AG - Global leader in CAR-T and gene therapy clinical programs.
2. Pfizer - Strong portfolio in gene-induced immunotherapy with strategic collaborations.
3. Adaptimmune Therapeutics - Specializes in T-cell receptor-based gene therapies.
4. Bluebird Bio, Inc. - Focused on oncolytic virotherapy and ex vivo gene therapies.
5. Krystal Biotech, Inc. - Expanding manufacturing and clinical capabilities in Asia-Pacific.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.